ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $36.79 billion. The enterprise value is $36.69 billion.
| Market Cap | 36.79B |
| Enterprise Value | 36.69B |
Important Dates
The next estimated earnings date is Thursday, July 31, 2025, after market close.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | May 8, 2025 |
Share Statistics
ResMed has 146.37 million shares outstanding. The number of shares has decreased by -0.07% in one year.
| Current Share Class | 146.37M |
| Shares Outstanding | 146.37M |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 74.72% |
| Float | 145.44M |
Valuation Ratios
The trailing PE ratio is 28.21 and the forward PE ratio is 24.66. ResMed's PEG ratio is 1.61.
| PE Ratio | 28.21 |
| Forward PE | 24.66 |
| PS Ratio | 7.35 |
| Forward PS | 6.73 |
| PB Ratio | 6.65 |
| P/TBV Ratio | 16.23 |
| P/FCF Ratio | 23.45 |
| P/OCF Ratio | 22.26 |
| PEG Ratio | 1.61 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.79, with an EV/FCF ratio of 23.38.
| EV / Earnings | 27.93 |
| EV / Sales | 7.31 |
| EV / EBITDA | 20.79 |
| EV / EBIT | 22.76 |
| EV / FCF | 23.38 |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.15.
| Current Ratio | 3.41 |
| Quick Ratio | 2.06 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.46 |
| Debt / FCF | 0.54 |
| Interest Coverage | 139.28 |
Financial Efficiency
Return on equity (ROE) is 25.81% and return on invested capital (ROIC) is 16.54%.
| Return on Equity (ROE) | 25.81% |
| Return on Assets (ROA) | 14.01% |
| Return on Invested Capital (ROIC) | 16.54% |
| Return on Capital Employed (ROCE) | 24.33% |
| Revenue Per Employee | $503,159 |
| Profits Per Employee | $131,589 |
| Employee Count | 9,980 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 2.09 |
Taxes
In the past 12 months, ResMed has paid $263.99 million in taxes.
| Income Tax | 263.99M |
| Effective Tax Rate | 16.74% |
Stock Price Statistics
The stock price has increased by +18.76% in the last 52 weeks. The beta is 0.77, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | +18.76% |
| 50-Day Moving Average | 234.88 |
| 200-Day Moving Average | 237.55 |
| Relative Strength Index (RSI) | 62.25 |
| Average Volume (20 Days) | 826,865 |
Short Selling Information
The latest short interest is 10.93 million, so 7.47% of the outstanding shares have been sold short.
| Short Interest | 10.93M |
| Short Previous Month | 9.11M |
| Short % of Shares Out | 7.47% |
| Short % of Float | 7.52% |
| Short Ratio (days to cover) | 9.56 |
Income Statement
In the last 12 months, ResMed had revenue of $5.02 billion and earned $1.31 billion in profits. Earnings per share was $8.91.
| Revenue | 5.02B |
| Gross Profit | 2.98B |
| Operating Income | 1.61B |
| Pretax Income | 1.26B |
| Net Income | 1.31B |
| EBITDA | 1.76B |
| EBIT | 1.61B |
| Earnings Per Share (EPS) | $8.91 |
Balance Sheet
The company has $944.84 million in cash and $839.77 million in debt, giving a net cash position of $105.07 million or $0.72 per share.
| Cash & Cash Equivalents | 944.84M |
| Total Debt | 839.77M |
| Net Cash | 105.07M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 5.55B |
| Book Value Per Share | 37.83 |
| Working Capital | 2.27B |
Cash Flow
In the last 12 months, operating cash flow was $1.65 billion and capital expenditures -$84.16 million, giving a free cash flow of $1.57 billion.
| Operating Cash Flow | 1.65B |
| Capital Expenditures | -84.16M |
| Free Cash Flow | 1.57B |
| FCF Per Share | $10.72 |
Margins
Gross margin is 59.37%, with operating and profit margins of 32.10% and 26.15%.
| Gross Margin | 59.37% |
| Operating Margin | 32.10% |
| Pretax Margin | 31.41% |
| Profit Margin | 26.15% |
| EBITDA Margin | 35.14% |
| EBIT Margin | 32.10% |
| FCF Margin | 31.24% |
Dividends & Yields
This stock pays an annual dividend of $2.12, which amounts to a dividend yield of 0.84%.
| Dividend Per Share | $2.12 |
| Dividend Yield | 0.84% |
| Dividend Growth (YoY) | 10.42% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 23.79% |
| Buyback Yield | 0.07% |
| Shareholder Yield | 0.91% |
| Earnings Yield | 3.57% |
| FCF Yield | 4.26% |
Analyst Forecast
The average price target for ResMed is $259.40, which is 3.20% higher than the current price. The consensus rating is "Buy".
| Price Target | $259.40 |
| Price Target Difference | 3.20% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 8.70% |
| EPS Growth Forecast (5Y) | 15.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 12.61 and a Piotroski F-Score of 8.
| Altman Z-Score | 12.61 |
| Piotroski F-Score | 8 |